Yukio Ando

Active 1973–2024

Also published as
Yukio ANDO
175
Papers
21,017
Citations
87
h-index
171
i10-index

Citations

Citations per year for Yukio Ando1978: 1 citations1980: 2 citations1981: 2 citations1982: 1 citations1983: 1 citations1984: 2 citations1985: 4 citations1986: 2 citations1987: 9 citations1988: 4 citations1989: 6 citations1990: 11 citations1991: 16 citations1992: 14 citations1993: 17 citations1994: 11 citations1995: 15 citations1996: 16 citations1997: 30 citations1998: 38 citations1999: 45 citations2000: 56 citations2001: 62 citations2002: 66 citations2003: 85 citations2004: 100 citations2005: 93 citations2006: 83 citations2007: 76 citations2008: 71 citations2009: 54 citations2010: 88 citations2011: 101 citations2012: 111 citations2013: 100 citations2014: 119 citations2015: 155 citations2016: 142 citations2017: 136 citations2018: 145 citations2019: 540 citations2020: 639 citations2021: 627 citations2022: 476 citations2023: 345 citations2024: 633 citations2025: 252 citations2026: 2 citations1979: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,563 citing papers, 23.3% of this breakdownJapan: 702 citing papers, 10.4% of this breakdownChina: 483 citing papers, 7.2% of this breakdownItaly: 442 citing papers, 6.6% of this breakdownUnited Kingdom: 409 citing papers, 6.1% of this breakdownGermany: 311 citing papers, 4.6% of this breakdownFrance: 279 citing papers, 4.1% of this breakdownSpain: 185 citing papers, 2.8% of this breakdownCanada: 180 citing papers, 2.7% of this breakdownNetherlands: 169 citing papers, 2.5% of this breakdownSweden: 150 citing papers, 2.2% of this breakdownPortugal: 140 citing papers, 2.1% of this breakdown
0%23.3%Other 25.4%

Fields

  • Medicine44.3%
  • Biochemistry, Genetics and Molecular Biology36.2%
  • Immunology and Microbiology3.1%
  • Pharmacology, Toxicology and Pharmaceutics2.9%
  • Neuroscience2.1%
  • Physics and Astronomy1.8%
  • Other9.6%

Topics

  • Amyloidosis: Diagnosis, Treatment, Outcomes8%
  • Alzheimer's disease research and treatments2.3%
  • Parathyroid Disorders and Treatments2.2%
  • Cancer Immunotherapy and Biomarkers2.1%
  • Peptidase Inhibition and Analysis1.3%
  • Drug Transport and Resistance Mechanisms1.3%
  • Other82.8%

Coauthors

All papers

Open in search
  1. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , NEURO-TTRansform Investigators, Anna Mazzeo, Aikaterini Papagianni, Mazen M. Dimachkie, Ioannis Zaganas, Edward Gane, Marco Luigetti, Lucía Galán Dávila, Michelle M. Mezei, Juan González Moreno, Pascal Cintas, Davide Pareyson, Rebecca Traub, Julie Khoury, Conrado J. Estol, Merrilee Needham, David Adams, Michael Polydefkis, Thomas H. Brannagan, Vera Bril, Shahram Attarian, Marcelo Rugiero, B. Jane Distad, Eleni Zamba Papanicolaou, Kon‐Ping Lin, Merrill D. Benson, Morton Scheinberg - JAMA 2023 cited by 207

  2. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation Cardiovascular Imaging 2019 cited by 475

  3. Repurposing Diflunisal for Familial Amyloid Polyneuropathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2013 cited by 701

  4. JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation Journal 2020 cited by 238

  5. Guideline of transthyretin-related hereditary amyloidosis for clinicians

    Authors: , , , , , , , , , , , - Orphanet Journal of Rare Diseases 2013 cited by 718

  6. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy

    Authors: , , , , , , , , , - Journal of Neurology 2020 cited by 315

  7. SIRT7 Controls Hepatic Lipid Metabolism by Regulating the Ubiquitin-Proteasome Pathway

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cell Metabolism 2014 cited by 218

  8. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis

    Authors: , , , , , , , , , , , , , - Amyloid 2022 cited by 130

  9. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation Cardiovascular Imaging 2019 cited by 210

  10. Angiopoietin-like Protein 2 Promotes Chronic Adipose Tissue Inflammation and Obesity-Related Systemic Insulin Resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Metabolism 2009 cited by 360

  11. SIRT7 has a critical role in bone formation by regulating lysine acylation of SP7/Osterix

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 108

  12. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis

    Authors: , , , , , , , , , , - Amyloid 2021 cited by 96

  13. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 cited by 131

  14. NSUN3-mediated mitochondrial tRNA 5-formylcytidine modification is essential for embryonic development and respiratory complexes in mice

    Authors: , , , , , , , , , , , - Communications Biology 2023 cited by 32

  15. Evolving landscape in the management of transthyretin amyloidosis

    Authors: , , , , , - Annals of Medicine 2015 cited by 244

  16. Myocardial Late Iodine Enhancement and Extracellular Volume Quantification with Dual-Layer Spectral Detector Dual-Energy Cardiac CT

    Authors: , , , , , , , , , , , , - Radiology Cardiothoracic Imaging 2019 cited by 99

  17. Autoimmune postural orthostatic tachycardia syndrome

    Authors: , , , , , , , , , , , - Annals of Clinical and Translational Neurology 2018 cited by 94

  18. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Gastroenterology 2020 cited by 71

  19. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , - Amyloid 2013 cited by 138

  20. Pim-1 controls NF-κB signalling by stabilizing RelA/p65

    Authors: , , , , , - Cell Death and Differentiation 2009 cited by 126

  21. Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping

    Authors: , , , , , , , , , , - American Journal of Neuroradiology 2016 cited by 86

  22. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    Authors: , , , , , , , , , , , , , , , , , , , , , - Neurology and Therapy 2021 cited by 56

  23. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of the Endocrine Society 2018 cited by 213

  24. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

    Authors: , , , , , , , , , , , , , , , , , - Neurology and Therapy 2022 cited by 29